[The role of biologics into the management of psoriasis: a consensus paper by the Psoriasis Study Group, Arbeitsgemeinschaft Dermatologische Forschung].
About 20% of all psoriasis patients require photo- and/or systemic therapy because of the severity of their disease. Side effects, contraindications, insufficient clinical responses, and lack of long-term efficacy underline the need for novel and improved anti-psoriatic therapies. In recent years, the technology has been established to generate therapeutic molecules from living cells capable of inhibiting disease-relevant mediators or cell-cell interactions. Several of these so-called biologics interfering with key steps in the immunopathogenesis of psoriasis have the potential to meet this need with regard to treating moderate to severe psoriasis. Here, the Psoriasis Study Group of the Arbeitsgemeinschaft Dermatologische Forschung (ADF) analyses the established anti-psoriatic treatment modalities. With the shortcomings of these options in mind, biologics with an immediate relevance for clinical application in the treatment of psoriasis are discussed. The focus is on their potential medical advantages along with safety aspects. Moreover, legal and economical aspects with an impact on the use of biologics are addressed.
Wolf-Henning
Boehncke
B
Zentrum der Dermatologie und Venerologie, Johann-Wolfgang-Goethe-Universität, Frankfurt am Main. Boehncke@em.unifrankfurt.de
Friedrich
Markus
M
Mrowietz
Ulrich
U
Reich
Kristian
K
Rosenbach
Thomas
T
Sticherling
Michael
M
Thaçi
Diamant
D
D015535:Arthritis, Psoriatic / Q000175:diagnosis / Q000188:drug therapy; D001688:Biological Products / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D017277:Drug Approval; D016527:Drug Costs / Q000706:statistics & numerical data; D005858:Germany; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D011565:Psoriasis / Q000188:drug therapy* / Q000191:economics / Q000276:immunology; D016896:Treatment Outcome; D014481:United States; D014486:United States Food and Drug Administration
D001688:Biological Products; D007166:Immunosuppressive Agents